Raymond James Financial’s 4D Molecular Therapeutics FDMT Stock Holding History

Raymond James Financial’s Portfolio FDMT Stock Details FDMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$3.46M	Sell	241,860 -489	-0.2%	-$6.36K	﹤0.01%	3080
2026 Q2	$3.22M	Sell	242,349 -23,798	-9%	-$232K	﹤0.01%	3108
2026 Q1	$2.48M	Sell	266,147 -211,358	-44%	-$1.84M	﹤0.01%	3182
2025 Q4	$3.58M	Buy	477,505 +6,235	+1%	+$63.2K	﹤0.01%	2786
2025 Q3	$4.1M	Buy	471,270 +15,800	+3%	+$94.4K	﹤0.01%	2609
2025 Q2	$1.69M	Buy	455,470 +161,091	+55%	+$566K	﹤0.01%	3217
2025 Q1	$951K	Buy	294,379 +181,475	+161%	+$855K	﹤0.01%	3530
2024 Q4	$629K	Buy	+112,904	New	+$886K	﹤0.01%	3763

Other funds holding FDMT

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return

VOYA Investment Management Atlanta, Georgia $109B AUM 51.53% 1-Year Est. Return

Raymond James Financial's FDMT Position: Q3 2026 in Review

Raymond James Financial reduced its 4D Molecular Therapeutics (FDMT) stake by 0.2% in Q3 2026, selling an estimated $6.36K and leaving 241,860 shares worth $3.46M. The position accounts for ﹤0.01% of the portfolio, ranked #3080.

Raymond James Financial first reported a position in FDMT in Q4 2024 and has held it in 8 quarters since. The position peaked at $4.1M in Q3 2025. 81 funds tracked by Wall St. Rank hold FDMT as of Q3 2026.

Raymond James Financial held 241,860 shares of 4D Molecular Therapeutics worth $3.46M as of Q3 2026.
Raymond James Financial sold 489 4D Molecular Therapeutics shares in Q3 2026, an estimated $6.36K.
4D Molecular Therapeutics made up ﹤0.01% of Raymond James Financial's portfolio in Q3 2026, its #3080 holding.
Raymond James Financial first reported a position in 4D Molecular Therapeutics in Q4 2024 and has held it in 8 quarters since.
Raymond James Financial's 4D Molecular Therapeutics position peaked at $4.1M in Q3 2025.
81 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q3 2026.

Based on Raymond James Financial's 13F filing for Q3 2026, filed 12 Nov 2026.